From the Journals

CRC risk: Raised by meat/alcohol, lowered by aspirin/NSAIDs


 

Increased risk

Consumption of both meat and alcohol was found to increase the risk for colorectal cancer.

Most of the meta-analyses of observational studies have reported a significant increase in risk (RR, 1.12-1.21) with meat consumption (particularly red and processed) and the incidence of colorectal cancer. Studies of the dose effect reported a 10%-30% increased risk for each increment of 100 g/day of total or red meat.

Alcohol consumption was also associated with a significantly increased risk. The higher the intake, the greater the risk. The risk was evident even at the lowest consumption doses that were investigated (1-2 drinks per day).

Balanced for the individual patient

Commenting on the article, Thomas J. George Jr, MD, professor of medicine and director, GI Oncology Program, the University of Florida Health Cancer Center, Gainesville, feels that the take-home message for clinicians and patients alike is that these data help to reinforce behaviors that have already been recommended.

“We know that excessive alcohol and red meat consumption is not healthy, so seeing that there may be a negative effect on colorectal cancer is just more evidence that we should be avoiding that and recommend avoiding that,” said Dr. George. “So yes, I recommend minimizing those, and likewise, a diet that is inclusive of fruits, vegetables, fiber, soy – perhaps as an alternative to meat consumption – is healthier than a diet devoid of these, so again, more reassuring data to support doing what we should already be doing.”

However, he pointed out that there are risks associated with medications such as NSAIDs and aspirin, including bleeding, gastric ulcer formation, and kidney damage. “The risks are low but very real,” Dr. George said. “So I think those recommendations need to be considered on a very individual level, balancing any other risk factors that the patient may have for both colorectal cancer, as well as risks from the medications.”

The study had no outside funding. The authors have disclosed no relevant financial relationships.

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

FDA clamps down on compliance for gluten-free products
Federal Practitioner
COVID-19 impact: Less chemo, immune checkpoint inhibitors, and steroids
Federal Practitioner
Aspirin may accelerate cancer progression in older adults
Federal Practitioner
Immunotherapy should not be withheld because of sex, age, or PS
Federal Practitioner
Mounting data support COVID-19 acute pancreatitis
Federal Practitioner
Infectious COVID-19 can persist in gut for weeks
Federal Practitioner
COVID-19 outcomes no worse in patients on TNF inhibitors or methotrexate
Federal Practitioner
COVID-19 prompts ‘democratization’ of cancer trials
Federal Practitioner
Global stomach cancer deaths decline as colorectal cancer deaths stagnate, rise
Federal Practitioner
The scope of under- and overtreatment in older adults with cancer
Federal Practitioner